MiniMed Group (MMED) SEC filings document the regulatory record of a Nasdaq-listed diabetes technology company focused on insulin delivery systems, CGMs, sensors, algorithms, and app-connected diabetes management. MiniMed's filings include annual reports, quarterly reports, proxy statements, and Form 8-K material event reports.
For MMED, the most relevant filings often relate to medical device operations and newly public company governance. Annual reports and 10-Q filings can describe business structure, risk factors, capital structure, financial results, clinical and regulatory matters, and disclosures tied to MiniMed's separation from Medtronic. Form 8-K filings have covered financial results, board appointments, executive compensation plans, officer departures, cybersecurity-related disclosures, and other material events.
Proxy statements are useful for reviewing director elections, auditor ratification, advisory compensation votes, and governance matters. Form 4 insider transaction filings can show reported purchases, sales, or equity awards by directors and officers when such filings are submitted. 10-K and 10-Q reports are especially important for understanding how MiniMed reports its diabetes technology business after becoming a public company.
AI-powered summaries can translate dense filing language into plain-English explanations, while real-time EDGAR updates can surface new MMED filings as they are released. These summaries are most useful when reviewing long annual reports, quarterly updates, proxy statements, and insider transaction disclosures.
MiniMed Group, Inc. (MMED) completed its separation from Medtronic on October 15, 2026, through an exchange offer in which Medtronic accepted 55,032,401 of its shareholders’ ordinary shares in exchange for 252,813,348 newly issued MiniMed common shares. The offer was 5.4x subscribed, and Medtronic no longer owns MiniMed shares.
Directors Linnea Burman, Scott Cundy, Laura Mauri, and Matthew R. Walter resigned effective October 15. The board was reduced from 11 directors to eight, and Amy Bricker was appointed an independent Class II director and joined the Nominating and Corporate Governance Committee. MiniMed amended its non-employee director compensation policy to provide a pro-rated annual grant of restricted stock units to eligible directors who become non-employee directors between annual shareholder meetings.
MiniMed Group, Inc. director Timothy A. Wicks received a grant of 11,795 restricted stock units on October 9, 2026, under the 2026 MiniMed Group, Inc. Long Term Incentive Plan. The units vest on the one-year anniversary of the grant date. His reported post-transaction position was 25,684 shares, including common stock shares to be issued in connection with vesting of one or more RSUs.
MiniMed Group, Inc. (MMED) director Kevin E. Lofton received a grant of 11,795 restricted stock units on October 9, 2026, under the 2026 MiniMed Group, Inc. Long Term Incentive Plan. The RSUs vest on the one-year anniversary of the grant date. His reported direct post-transaction position was 39,573 shares of common stock, including shares to be issued in connection with the vesting of one or more RSUs.
MiniMed Group, Inc. (MMED) director D. Keith Grossman received a grant of 11,795 restricted stock units on October 9, 2026, under the 2026 Long Term Incentive Plan. The RSUs vest on the one-year anniversary of the grant date. His reported post-transaction position was 25,684 shares of common stock, including shares to be issued in connection with vesting of one or more RSUs.
MiniMed Group, Inc. (MMED) granted director David J. Endicott 11,795 restricted stock units (RSUs) on October 9, 2026, under its 2026 Long Term Incentive Plan. The RSUs vest on the one-year anniversary of the grant date. The reported post-transaction amount is 11,795 shares and includes common stock to be issued in connection with RSU vesting.
MiniMed Group, Inc. director Glenn A. Eisenberg acquired a grant of 11,795 restricted stock units on October 9, 2026, under the 2026 MiniMed Group, Inc. Long Term Incentive Plan. The units vest on the grant's one-year anniversary. His reported direct holdings following the transaction were 25,684 shares, including common stock to be issued in connection with vesting of one or more RSUs.
MiniMed Group, Inc. reported that stockholders approved all four proposals at its October 9, 2026 annual meeting. Stockholders elected Kevin E. Lofton, David J. Endicott, D. Keith Grossman and Timothy (Tim) A. Wicks as Class I directors to serve until the 2029 Annual Meeting, and ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending April 30, 2027.
Stockholders approved named executive officer compensation in a non-binding, advisory vote. On the frequency proposal, 276,205,804 votes favored annual votes, compared with 1,894 for every two years and 7,990 for every three years. MiniMed determined it will hold future non-binding, advisory votes on named executive officer compensation every one year until the next required vote on such frequency.
MiniMed Group, Inc. reports that Sheila A. Denton, SVP, Gen. Counsel & Corp. Sec., received a grant of 58,939 restricted stock units on October 1, 2026, under the 2026 MiniMed Group, Inc. Long Term Incentive Plan. The units vest in approximately equal one-third increments on the first, second and third anniversaries of the grant date. Her reported post-transaction total was 58,939 shares, including common stock to be issued upon RSU vesting.
MiniMed Group, Inc. is registering up to 225,361,295 newly issued common shares for Medtronic plc’s exchange offer, in which Medtronic will exchange its ordinary shares validly tendered and not withdrawn for MiniMed shares. The offered amount represents approximately 80.1% of MiniMed’s outstanding common shares as of September 3, 2026. For each $100 of Medtronic shares accepted, holders are expected to receive approximately $107.53 of MiniMed stock, subject to an upper limit of 4.5939 MiniMed shares per Medtronic share; there is no minimum exchange ratio. The calculation values MiniMed at 93% of its average VWAP, a 7% discount, but if the cap applies, holders may receive less than $107.53 for each $100 tendered.
The final ratio will use average daily VWAPs over three trading days; if the offer is not extended or terminated, those dates are October 5–7, 2026, and the offer expires October 9, 2026. Completion is conditional, including issuance of at least 112,680,647 MiniMed shares, receipt of a tax opinion, and effectiveness of the registration statement. If fully subscribed and Medtronic accepts no additional shares, it would retain approximately 9.76% of MiniMed, based on outstanding shares as of September 3, 2026. If oversubscribed, Medtronic may accept additional Medtronic shares up to 2% of its total outstanding shares.